New study aims to find best CMV prevention for kidney transplant patients

This study looks at two different approaches to prevent cytomegalovirus (CMV) infection in people who have received a kidney transplant from a living donor. The participants are at intermediate risk for CMV and are given standard anti-rejection medication. The goal is to see which strategy—daily preventive medication or monitoring and treating only if the virus appears—works better to keep patients healthy. Results may help doctors choose the best prevention plan for similar patients.